OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Last trade$31.26
Day change-$0.24 (-0.76%)
Day range$31.07 – $32.00
Volume92,474
Market cap$822M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$822.48M
Price / earnings
—
Price / book
2.42×
Price / sales
3.11×
EV / sales
3.42×
EV / EBITDA
801.02×
Profitability
Earnings per share
-$1.30
Return on assets
-6.66%
Return on equity
-9.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.29×
Current ratio
4.55×
Quick ratio
2×
Cash ratio
0.31×
Cash flow
Price / cash flow
65.82×
Price / free cash flow
258.64×
Free cash flow
$3.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KIDS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$72.66M
$70.51M
$59.36M
$61.61M
$61.25M
$61.08M
$52.41M
$52.67M
Cost of revenue
$18.69M
$18.14M
$15.97M
$16.5M
$15.98M
$17.06M
$14.15M
$17.1M
Gross profit
$53.98M
$52.37M
$43.39M
$45.11M
$45.27M
$44.02M
$38.26M
$35.57M
Selling, general and administrative
$55.13M
$54.11M
$49.49M
$48.35M
$47.81M
$49.55M
$46.85M
$41.22M
Research and development
$2.47M
$2.33M
$2.23M
$2.26M
$2.33M
$2.16M
$2.35M
$2.92M
Total operating expenses
$58.2M
$56.43M
$51.73M
$53.28M
$54.7M
$54.68M
$49.24M
$49.62M
Operating income
-$4.23M
-$4.07M
-$8.34M
-$8.17M
-$9.43M
-$10.66M
-$10.98M
-$14.06M
Interest expense
-$2.62M
-$2.53M
-$2.1M
-$1.93M
-$1.82M
-$1.12M
-$1.13M
-$1.32M
Income before taxes
-$6.04M
-$6.93M
-$10.86M
-$9.76M
-$11.9M
-$7.06M
-$10.46M
-$16.41M
Income taxes
-$109K
$234K
-$171K
$340K
-$125K
$49K
$196K
-$340K
Net income
-$5.93M
-$7.16M
-$10.69M
-$10.1M
-$11.77M
-$7.11M
-$10.66M
-$16.07M
Net income attributable to common shareholders
-$5.93M
-$7.16M
-$10.69M
-$10.1M
-$11.77M
-$7.11M
-$10.66M
-$16.07M
EBITDA
$2.01M
$1.64M
-$2.61M
$96K
$433K
-$2.52M
-$5.89M
-$4.57M
Basic earnings per share
-$0.25
-$0.30
-$0.45
-$0.43
-$0.50
-$0.30
-$0.46
-$0.69
Diluted earnings per share
-$0.25
-$0.30
-$0.45
-$0.43
-$0.50
-$0.30
-$0.46
-$0.69
Recent news
Company coverage with links to the original publishers.
OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The upgrade positions the company in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving earnings outlook and institutional investor interest.
OrthoPediatrics raised its 2026 revenue guidance to $270-273 million, with Q3 revenue growing 19% year-over-year to $72.7 million. The company is benefiting from a product super cycle with new pediatric surgical implants, expansion of its non-surgical bracing clinic network to over 60 locations, and disciplined capital allocation that has generated positive free cash flow of $1.6 million in Q3.
OrthoPediatrics (KIDS) reported a quarterly loss of $0.23 per share, beating the consensus estimate of $0.25 loss, with an 8% earnings surprise. Revenue of $72.66 million also exceeded expectations by 6.01%. The stock has gained 35.3% year-to-date, outperforming the S&P 500's 12.1% gain. However, the company maintains a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
OrthoPediatrics Corp. announced the full commercial launch of its 3P Pediatric Plating Platform Hip System following a successful limited launch with over 350 surgical implantations. The system, designed for pediatric hip trauma and deformity correction, is now broadly available to pediatric orthopedic surgeons throughout the United States and represents the first in a planned portfolio of Pediatric Plating Platform systems.
OrthoPediatrics Corp. announced a distribution partnership with MY01 to expand access to Continuous Perfusion Sensing Technology for diagnosing acute compartment syndrome in children, focusing on improving trauma monitoring and patient outcomes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.